Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 06, 2018 10:30 ET | Source: Novartis Pharma AG

Novartis investigational BYL719 (alpelisib) plus fulvestrant consistently improved PFS in patients with PIK3CA mutated HR+/HER2- advanced breast cancer in new SOLAR-1 analyses

BYL719 plus fulvestrant meaningfully prolonged PFS vs fulvestrant alone in patients with PIK3CA mutated HR+/HER2- advanced breast cancer after progression on an aromatase ...
December 03, 2018 01:15 ET | Source: Novartis Pharma AG

Novartis announces FDA filing acceptance and Priority Review of AVXS-101, a one-time treatment designed to address the genetic root cause of SMA Type 1

The AVXS-101, now known as ZOLGENSMA® (onasemnogene abeparvovec-xxxx)[1], filing is supported by data from the START trial which demonstrated a dramatic increase in survival and transformative...
December 02, 2018 10:15 ET | Source: Novartis Pharma AG

Real-world data show Novartis drug Revolade® improves outcomes for ITP patients compared to other second-line therapies

Revolade (eltrombopag) showed lower rate of bleeding-related episodes and similar rate of thrombotic events vs. romiplostim, rituximab and splenectomy, in a retrospective analysis of US electronic...
December 01, 2018 14:30 ET | Source: Novartis Pharma AG

Novartis announces longer-term analyses from pivotal Kymriah® trials that showed durable responses are maintained in patients with advanced blood cancers

In the updated analysis from ELIANA, Kymriah demonstrated an 82% remission rate within 3 months in pediatric patients with r/r ALL; relapse-free survival was 62% at 24 months, with median duration...
December 01, 2018 10:15 ET | Source: Novartis Pharma AG

Novartis announces new crizanlizumab (SEG101) data analysis in sickle cell disease, and investment in SENTRY clinical program

New post-hoc analysis of SUSTAIN study, presented at ASH 2018, highlights results among patients who were treated per protocol compared with all randomized patientsCrizanlizumab, a monthly...
November 29, 2018 01:15 ET | Source: Novartis Pharma AG

Novartis announces EU approval of Gilenya® for children and adolescents with MS, making it the first and only oral disease-modifying treatment for these patients in Europe

Approval based on landmark PARADIGMS study showing Gilenya (fingolimod) significantly reduced relapse rates by 82% vs interferon beta-1a; additionally, 85.7% of Gilenya patients were relapse-free...
November 27, 2018 01:15 ET | Source: Novartis Pharma AG

Sandoz receives eighth European Commission approval for a biosimilar with Ziextenzo® (pegfilgrastim)

Biosimilar Ziextenzo® (pegfilgrastim), a long-acting version of supportive oncology medicine filgrastim, is now approved for use in all reference medicine indications [1] Ziextenzo is indicated...
November 27, 2018 01:00 ET | Source: Novartis Pharma AG

Alcon to highlight its vision, strategy and benefits as a standalone company to investors and analysts in New York and London

Alcon is the global leader in the highly attractive and growing $23 billion eye care devices market Market leading development capabilities and innovation investments Clearly defined near and...
November 23, 2018 01:15 ET | Source: Novartis Pharma AG

Novartis announces landmark EU approval for one-time gene therapy Luxturna® to restore vision in people with rare inherited retinal disease

Luxturna* (voretigene neparvovec) is the first gene therapy to treat an inherited retinal disease, indicated for children and adults with vision loss caused by mutations in both copies of the...
November 20, 2018 08:15 ET | Source: Novartis Pharma AG

Novartis rises to second place in 2018 Access to Medicine Index

Company leads the industry in access-to-medicine management thanks to long- term commitment, as well as ongoing innovation in access to healthcare Novartis moves up one position from number 3 in...